Does Medicare Advantage Cover Repatha (Evolocumab)?

Repatha (generic name evolocumab) is a monoclonal antibody that inhibits PCSK9, given as a subcutaneous injection every two weeks (140 mg) or once monthly (420 mg). It is distinct from alirocumab (Praluent, a different PCSK9 monoclonal antibody) and from inclisiran (Leqvio, a small interfering RNA that reduces PCSK9 production rather than blocking the protein directly). All three lower LDL cholesterol, but they have different Medicare benefit pathways, discussed below.

Repatha (evolocumab) is FDA-approved to reduce LDL cholesterol in adults with HeFH or HoFH and in adults with established cardiovascular disease, and to reduce the risk of cardiovascular events in that established-disease population, per the FDA-approved prescribing information. Medicare Advantage plans cover it through Part D, but almost all plans require prior authorization and step therapy through a high-intensity statin plus ezetimibe first, and it is placed on the highest-cost specialty formulary tier. In practice this means a prior-authorization request submitted without complete statin/ezetimibe trial documentation, current labs, and a clear diagnosis is likely to be denied on first pass, independent of whether the patient ultimately qualifies.

How Medicare Advantage plans classify Repatha on formulary

Medicare Advantage plans with integrated Part D benefits typically place Repatha on the specialty tier (often labeled Tier 5), which carries the highest cost-sharing on the plan's formulary, generally a percentage coinsurance rather than a flat copay. CMS requires Part D sponsors to maintain broad access to at least one drug in each protected or clinically important class, and PCSK9 inhibitors are widely represented across Medicare Advantage and standalone Part D formularies, though exact formulary inclusion rates vary by plan year and carrier and should be checked directly against a plan's current formulary rather than assumed.

Specialty-tier placement matters practically because CMS's standard tiering-exception process, which lets a beneficiary ask for a lower copay on a non-preferred drug, generally does not apply to specialty tiers. For a drug in this tier, the main lever that changes what a patient pays over the course of a year is reaching the annual Part D out-of-pocket cap described below, not a tiering appeal.

Prior authorization: what plans typically ask for

Every major Medicare Advantage carrier requires prior authorization before dispensing Repatha. Plans generally build their criteria around the FDA-approved indications, so the request needs to establish:

• A confirmed diagnosis of HeFH, HoFH, or clinical ASCVD (history of myocardial infarction, stroke, or peripheral arterial disease)
• LDL-C remaining above the plan's threshold despite a trial of statin therapy at the maximally tolerated dose, or documented statin intolerance
• A recent fasting lipid panel, usually required within roughly 30 to 90 days of submission
• A list of lipid-lowering agents already tried, with doses, dates, and reasons for discontinuation
• For HeFH, either genetic confirmation or a validated clinical scoring tool (for example, the Dutch Lipid Network Score)

Authorization periods commonly run 6 to 12 months, after which reauthorization typically requires updated labs showing a meaningful LDL-C response to treatment. Exact thresholds (for example, the specific LDL-C cutoff that counts as "above goal," or the percentage drop required at reauthorization) differ by plan and should be confirmed against the specific plan's medical policy rather than treated as fixed across all Medicare Advantage carriers.

Step therapy: the most common reason for denial

Step therapy is the most frequent barrier to first-pass Repatha approval on Medicare Advantage. The typical sequence plans require before they will authorize a PCSK9 inhibitor is:

1. A high-intensity statin (commonly atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a period on the order of 8 to 12 weeks
2. Addition of ezetimibe 10 mg for a similar trial period
3. In a growing number of plans, a trial of bempedoic acid (Nexletol) or the bempedoic acid/ezetimibe combination (Nexlizet) before a PCSK9 inhibitor is approved

Bempedoic acid has trial evidence supporting cardiovascular benefit in statin-intolerant patients (a large randomized cardiovascular outcomes trial, published in the New England Journal of Medicine), which is part of why some plans added it as an intermediate step; the exact magnitude of benefit reported in that trial should be verified against the original publication before it is cited as a specific number in patient-facing material, since this draft could not confirm a verified primary-source link for it.

Patients with documented, complete statin intolerance (commonly defined in guideline literature as inability to tolerate at least two statins, including one at the lowest starting dose, due to muscle symptoms that resolve on discontinuation) may have the statin step waived by some plans, but most still require an ezetimibe trial. Vague documentation ("patient cannot tolerate statins") is a common reason plans reject an intolerance claim; specifics on the statin name, dose, timeline, and symptom matter.

Repatha prior-authorization decision framework

Use this to sort a specific patient situation into the approval path most likely to work, and to know what to prepare before submitting.

This framework reflects common Medicare Advantage prior-authorization patterns for PCSK9 inhibitors as described in the FDA label and the AHA/ACC cholesterol guideline; individual plan medical policies vary and should be checked directly, since specific cutoffs, authorization windows, and reauthorization thresholds differ by carrier and plan year.

What Repatha costs after approval

List price and specific deductible amounts change from year to year, so any dollar figure here should be checked against current CMS and manufacturer pricing information rather than treated as fixed. As a general structural point: under the Inflation Reduction Act, Medicare Part D has carried an annual out-of-pocket spending cap for enrollees since 2025, after which a beneficiary's cost-sharing for covered Part D drugs drops to zero for the remainder of the plan year. Before that beneficiary reaches the annual cap, specialty-tier coinsurance (commonly in the 25 percent to 33 percent range on many plans) applies to a drug in Repatha's tier, so monthly out-of-pocket cost during that phase can be substantial for a self-administered biologic.

Manufacturer copay cards, including any card Amgen offers for Repatha, cannot be used by Medicare beneficiaries because federal law (the Anti-Kickback Statute) prohibits combining copay assistance with Medicare, Medicaid, or other federal healthcare programs. Amgen has historically offered a separate patient assistance program for income-qualifying patients; eligibility criteria and income thresholds should be confirmed directly with the manufacturer, since program terms change.

Appealing a Medicare Advantage denial

Medicare Advantage enrollees have CMS-mandated appeal rights when a plan denies Repatha.

The first step is a plan redetermination: the beneficiary or prescriber submits a written request, generally within 60 days of the denial notice, or requests an expedited review if a standard timeline could cause serious harm. A strong appeal typically includes updated labs, a letter of medical necessity explaining why alternatives are inadequate, and documentation that step therapy was completed.

If the plan upholds its denial, the case advances to an independent external reviewer that is not bound by the plan's original decision. Appeal reversal rates vary by year and by the completeness of the documentation submitted; a specific reversal percentage was not available from a source this draft could verify, so no number is cited here. Beyond that level, further appeal stages exist (an administrative hearing, an appeals council, and ultimately federal court), though most Repatha disputes resolve before reaching that point.

If a prescriber requests expedited review and the plan denies the expedited request, the plan is required to forward the case to independent review on an accelerated basis, which matters for patients with very high LDL-C and a recent cardiovascular event.

Repatha vs. Praluent (alirocumab) vs. Leqvio (inclisiran) on Medicare

Alirocumab (Praluent) is a second PCSK9 monoclonal antibody with a cardiovascular outcomes trial in patients with recent acute coronary syndrome, and its Medicare Advantage coverage criteria (prior authorization, step therapy) are broadly similar to Repatha's, though plan-level formulary preference between the two varies and should be checked at medicare.gov's Plan Finder tool or directly with the plan.

Inclisiran (Leqvio) works differently: it is a small interfering RNA that reduces PCSK9 production and is given by a healthcare professional in a clinical setting twice yearly after two initial loading doses, rather than self-injected at home. Because it is provider-administered, inclisiran is generally billed under Part B (the medical benefit) rather than Part D, which changes the cost structure: Part B cost-sharing is typically 20 percent coinsurance after the annual Part B deductible, with no specialty-tier coinsurance or Part D coverage-gap dynamics. Whether that is cheaper for a given patient depends on their supplemental coverage and the administering provider's billing arrangement, and should be confirmed with the specific plan rather than assumed.

What is established and what is not

Established: evolocumab is FDA-approved for HeFH, HoFH, and established ASCVD with an LDL-lowering and cardiovascular risk-reduction indication in the ASCVD population, and Medicare Advantage plans cover it under Part D subject to utilization management. Established: prior authorization and step therapy through statin and ezetimibe are near-universal plan requirements, and specialty-tier coinsurance applies until a beneficiary reaches the annual Part D out-of-pocket cap.

Plausible but plan-dependent: whether a third step (bempedoic acid) is required, the exact LDL-C thresholds used, and the exact appeal-success rate at each review stage. These vary by carrier, by plan year, and were not independently verifiable from the source material for this draft; a reader should confirm them against the specific plan's current medical policy or CMS's published appeals data before relying on a precise figure.

Not established from the material reviewed here: any claim that a specific percentage of appeals succeed, an exact current WAC price, or an exact current Part B or Part D deductible amount. Those change annually and require verification against CMS and manufacturer sources at the time of reading.